NEW YORK, June 3, 2004 (PRIMEZONE) -- Advanced Plant Pharmaceuticals, Inc. (OTCBB:APPI) announced today that it had successfully been delisted from the Berlin-Bremen Stock Exchange. The company had requested its counsel to seek immediate delisting when it had ascertained that the company had been listed on the Berlin Exchange without the company's prior knowledge, consent or authorization. The company believes that its shares had been listed on the Berlin-Bremen Exchange on or about January 27, 2004.
"Advanced Plant Pharmaceuticals, as well as more then 200 other U.S. publicly traded companies, have been listed and traded on the Berlin-Bremen Stock Exchange without their permission or application," said David Lieberman, CEO of Advanced Plant Pharmaceuticals. "Although initially management had no concern about this unsolicited and unapplied for listing, recent revelations have initiated reconsideration. The financial media has recently been reporting that these coincidental wholesale listings may be part of an effort by certain brokers to avoid U.S. restrictions against 'naked short selling.' We deemed it prudent and in the interest of our shareholders to request that APPI be de-listed from the Berlin Exchange to eliminate the possibility of certain parties to utilize an overseas exchange to engage in arbitrage and short selling."
About Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of plant-based dietary and health supplements. The Company has a patent-pending process that utilizes whole plants to manufacture all-natural dietary and health supplements. APPI uses this process to manufacture products, which the company distributes worldwide through various marketing and distribution contracts. Corporate website: http://www.advancedplantpharm.com
Forward-Looking Statements
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.